Aktis Oncology, Inc. (AKTS) vs Immatics N.V. (IMTX)
A side-by-side comparison of Aktis Oncology, Inc. and Immatics N.V. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AKTS
Aktis Oncology, Inc.
$18.72HealthcareDelayed quote: Oct 6, 2026, 11:31 AM EDT
IMTX
Immatics N.V.
$7.70HealthcareDelayed quote: Oct 6, 2026, 11:30 AM EDT
Total return — AKTS vs IMTX
growth of $100 · dividends reinvested · last 1yAKTS -17.3% (-17.3%/yr)IMTX -15.7% (-15.7%/yr)IMTX compounded faster over this window
AKTS IMTX
AKTS vs IMTX: by the numbers
- •IMTX is the larger company ($1.03B vs $1000M market cap).
- •Both run net losses; IMTX's is the smaller (-493.26% vs -727.04% net margin).
Metrics side by side
Valuation
| Metric | AKTS | IMTX |
|---|---|---|
| P/S ratio | 99.38 | 21.28 |
| P/B ratio | 2.06 | 2.26 |
Profitability
| Metric | AKTS | IMTX |
|---|---|---|
| Gross margin | 100.00% | 100.00% |
| Operating margin | -1149.52% | -377.11% |
| Net margin | -727.04% | -493.26% |
| ROE | -15.09% | -52.47% |
| ROIC | -16.54% | -53.36% |
Growth (annualized)
| Metric | AKTS | IMTX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 6.40% |
| Total return CAGR (5Y) | N/A | -9.88% |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.